Clinical trials: Microbiome
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
Ulcerative Colitis
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.
- Trial name
- NCT02618187
- Testing
- SER-287, Vancomycin Pre-Treat
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Seres Therapeutics, Inc.
Healthy Volunteers
Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds
This single center, randomized, 15-day clinical trial is being conducted to assess the changes to the skin microbiome of induced wounds on the back in approximately 35 healthy adult subjects aged 18-55 years, with Fitzpatrick…
- Trial name
- NCT03365934
- Testing
- ADHESIVE BANDAGE #1, ADHESIVE BANDAGE #2, ADHESIVE BANDAGE #3
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Oral Health
A Study to Evaluate the Effect of a Stannous Fluoride Toothpaste on the Oral Microbiome
The aim of this study is to evaluate the effect of a toothpaste containing stannous fluoride (SnF2) over time on the oral bacterial composition and activity and to explore its effect in comparison to a regular fluoride toothpaste.
- Trial name
- NCT06048809
- Testing
- Stannous Fluoride Toothpaste (Sensodyne Repair and Protect), Regular Fluoride Toothpaste (Colgate Cavity Protection)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- HALEON
Ulcerative Colitis
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
- Trial name
- ECO-RESET (NCT03759041)
- Testing
- Vancomycin Pre-Treatment, SER-287
- Where
- 93 sites in United States, Canada
- Volunteers
- 203 people
- Sponsor
- Seres Therapeutics, Inc.
Autistic Disorder
28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
SB-121 is being developed for use in the treatment of autistic disorder (AD). This study is a multiple-dose, randomized, double-blind, placebo-controlled, cross-over single-site Phase I study.
- Trial name
- NCT04944901
- Testing
- SB-121
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Scioto Biosciences, Inc.
Rhinosinusitis Chronic, Microbiome
Impact of Symbiofilm On Nasal Microbiota
Healsea® chronic is CE marked medical device indicated in adults for the treatment of nasal symptoms of chronic rhinosinusitis. This is an hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract (0.2%)…
- Trial name
- ISONAM (NCT05015530)
- Testing
- Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Lallemand Pharma AG